FIELD: medicine.
SUBSTANCE: there are described versions of polypeptides specifically binding human DR5 each of which contains CDR versions containing a high-limited variety of amino acid sequences. There are described versions of polypeptides fused with at least a portion of protein, viral envelopes specifically binding human DR5. There are offered: a coding nucleic acid, an expression vector, as well as a cell for polypeptide expression containing the vector. What is also described is a method for producing the polypeptide by cell culture and a method for selecting an antigen-binding variable domain using the polypeptide. Besides, there are presented compositions and methods for using for the purpose of treating a malignant tumour and conditions related to the immune system.
EFFECT: use of the invention can find application in medicine in treating and diagnosing the tumour diseases.
88 cl, 29 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST SIGLEKA-15 FOR TREATING DISEASE ASSOCIATED WITH LOSS OF BONE MASS | 2010 |
|
RU2596392C2 |
| DOUBLE SPECIFICITY ANTIBODIES | 2014 |
|
RU2732032C2 |
| NEW FORM OF IL33, MUTATED FORMS OF IL33, ANTIBODIES, ANALYZES AND METHODS OF USING THEM | 2016 |
|
RU2736299C2 |
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| ANTIBODIES, CAPABLE OF SPECIFIC CONNECTING WITH HER2 | 2014 |
|
RU2628094C2 |
| NEUTRALISING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USING THEM | 2009 |
|
RU2553325C2 |
| ANTIBODIES THAT BIND TO PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) | 2013 |
|
RU2689953C2 |
| ANTI-CLUSTERIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND THEIR USE FOR TUMOURS VOLUME REDUCTION | 2010 |
|
RU2627163C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
